Latest Tax Refunds News

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Andromeda Metals has made significant strides in advancing its Great White Project, progressing funding efforts for Stage 1A+ and securing key operational milestones. The company also bolstered its leadership with new board appointments and received a substantial tax refund, positioning it for a critical investment decision.

Alliance Nickel Ltd has completed a definitive feasibility study for its NiWest Nickel-Cobalt Project, revealing strong financial metrics, increased ore reserves, and strategic collaborations with global automakers. The project is positioned to become a low-cost, sustainable supplier of high-purity nickel and cobalt for the burgeoning electric vehicle market.

Nimy Resources advances its Mons Project with significant high-grade copper and gallium mineralisation confirmed at Masson and Block 3 East prospects, supported by a successful capital raise and a CSIRO research grant.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

Elixir Energy wraps up Daydream-2 well operations and prepares for next appraisal in a strengthening gas market, while progressing farmout talks for Australian and Mongolian assets.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.

Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.

Activeport Group Ltd reported steady revenue of $2.5 million in Q2 FY25, maintaining a stable cost structure post-restructure and positioning itself for growth through new projects and a significant GPU orchestration licensing deal.

Hastings Technology Metals has secured a strategic non-binding MOU with Saudi Arabia’s Ministry of Investment to explore a rare earths processing facility, while reporting encouraging developments at its Yangibana Project and maintaining solid financial footing.

EcoGraf Limited advances its vertically integrated battery anode materials business with a significant UFK loan mandate and progress across upstream, midstream, and downstream operations.

Tryptamine Therapeutics has reported successful Phase 1b results for its IV-infused psilocin candidate TRP-8803 and promising interim data for oral psilocybin TRP-8802 in IBS treatment, while securing $6 million in new funding to accelerate clinical development.